Catalog Number : 500-P36
Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hRANTES. Anti-Human RANTES specific antibody was purified by affinity chromatography employing immobilized hRANTES matrix.
|Application:||ELISA, Western Blot, Neutralization, Immunohistochemistry|
Anti-Human RANTES (BioGems Catalog #300-06)
This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentration is 2.0 µg/ml with an overnight incubation at 4°C. An HRP-labeled polymer detection system was used with an AEC chromogen. Heat induced antigen retrieval with a pH 6.0 Sodium Citrate buffer is recommended. Optimal concentrations and conditions may vary.
To yield one-half maximal inhibition [ND50] of the biological activity of hRANTES (100 ng/ml), a concentration of 0.4-0.6 µg/ml of this antibody is required.
To detect hRANTES by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems' Biotinylated Anti-Human RANTES (60-285BT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hRANTES.
To detect hRANTES by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hRANTES is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.